Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Liabilities and Shareholders Equity (2024 - 2025)

Xilio Therapeutics (XLO) has disclosed Liabilities and Shareholders Equity for 2 consecutive years, with $154.7 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 117.64% to $154.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $525.9 million through Dec 2025, up 65.27% year-over-year, with the annual reading at $154.7 million for FY2025, 117.64% up from the prior year.
  • Liabilities and Shareholders Equity hit $154.7 million in Q4 2025 for Xilio Therapeutics, up from $133.7 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $154.7 million in Q4 2025 to a low of $71.1 million in Q4 2024.